PUBLICATIONS

ABVAC40

AB1601 phase 2 study of ABvac40, an anti-Aβ40 vaccine: safety and immunogenicity of a cross-over extension

Poster presentation AAIC 2023. María Pascual-Lucas, et al.

ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile

Poster presentation CTAD 2022—ABVac40 Safety profile information Montañes M, Martín C, Castillo S et al.

UPDATE PHASE 2 STUDY OF ABVAC40, AN ACTIVE VACCINE ANTI-AΒ40 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR VERY-MILD ALZHEIMER’S DISEASE

Poster Presentation ADPD 2022 – TOP LINE DATA (Part A) Phase 2 ABvac40 Molina E, Castillo S, Lacosta AM et al.

Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta AM, Pascual-Lucas M, Pesini P, et al. Alzheimers Res Ther. 2018; 10:12.

ABtest-ms

Clinical utility of an antibody-free LC-MSmethod to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

Jose Antonio Allué, et al. Alzheimer’s Dementia Diagnosis Assessment Disease Monitoring 2023

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

Chun Ming Young, et al. Frontiers in Anging Neuroscience 2023.

Association of plasma Aβ42/Aβ40 with episodic memory performance and brain atrophy in individuals at risk of Alzheimer’s disease

Poster presentation ADPD 2023. María Pascual-Lucas, et al.

Clinical performance of an antibody‑free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

Pascual-Lucas M, Allué JA, Sarasa L et al. Alzheimer’s Research & Therapy 2023; 15:2

Comparative performance of plasma Aβ42/Aβ40 and p‐tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline.

Poster presentation CTAD 2022—ABtest MS FACEHBI Cohort Pascual-Lucas M, Allué JA, Sarasa L et al.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Janelidze S, Palmqvist S, Leuzy A et al. Alzheimer’s Dement 2022; 18:283-293

Plasma Aβ42/Aβ40, measured by a novel mass spectrometric method, identifies early amyloid deposition in individuals at risk of Alzheimer’s disease (FACEHBI Cohort)

Oral Presentation ADPD 2022 – AbtestMS_FACEHBI Allué JA, Sarasa L, Pascual-Lucas M

ACCURATE DISCRIMINATION OF BRAIN AMYLOID STATUS IN THE MULTI-CENTRIC A4 STUDY BY PLASMA Aβ42/Aβ40 MEASURED WITH A NOVEL HPLC-MS/MS METHOD

Poster Presentation ADPD 2022 – AbtestMS_A4 Study Sarasa L, Pascual-Lucas M, Allué JA et al.

The global Alzheimer’s Association round robin study on plasma amyloid β methods

Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen N, Leuzy A, Palmqvist S et al. Nature Aging 2021; 1:114–123

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

Jang H, Kim Js, Lee HJ et al. Alz Res Therapy 2021; 13:179

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Janelidze S, Teunissen CE, Zetterberg H et al. JAMA Neurol. 2021;78:1375-1382.

ABtest-ia

ABtest-IA: A NEW RELIABLE TOOL FOR THE QUANTIFICATION OF Aβ40 AND Aβ42 IN CSF

Poster presentation AAIC 2022—ABtest IA CSF Validation Fandos N, Romero J, Pascual-Lucas M et al.

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Verberk IMW, Misdorp E, Koelewijn J et al. Alzheimers Dement 2022; 18:1484-1497.

The global Alzheimer’s Association round robin study on plasma amyloid β methods

Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain

Burnham SC, Fandos N, Fowler C, et al. Brain Communications. 2020; 2, 1-7.

Total Abeta42/Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis

Doecke JD, Pérez-Grijalba V, Fandos N, et al. Neurology. 2020; 94: e1580-e1591.

Plasma Abeta42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study

Pérez-Grijalba V, Romero J, Pesini P, et al. J Prev Alzheimers Dis. 2019-b; 6:34-41.

Plasma Abeta42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Pérez-Grijalba V, Arbizu J, Romero J, et al. Alzheimers Res Ther. 2019; 11:96.

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Risacher SL, Fandos N, Romero J, et al. Alzheimers Dement (Amst). 2019; 11:510-519.

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

De Rojas I, Romero J, Rodríguez-Gómez O, et al. Alzheimers Res Ther. 2018; 10:119.

Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals.

Fandos N, Pérez-Grijalba V, Pesini P, et al. Alzheimers Dement (Amst). 2017; 8:179-187.

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Abeta40 and Abeta42 Peptides in Plasma.

Pérez-Grijalba V, Fandos N, Canudas J, et al. J Alzheimers Dis. 2016; 54:751-62.